Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
1366302-52-4
Molecular formula
C44H62N6O17
Molecular weight
947 g/mol
Drug class
PSMA-targeting liganddiagnostic radiopharmaceutical component for gallium-68 PET imaging
Mechanism of action
The Glu-urea-Lys(Ahx) peptide ligand binds prostate-specific membrane antigen (PSMA) on prostate epithelial cells and commonly overexpressed on prostate cancer cells. When conjugated to the HBED-CC chelator and radiolabelled with gallium-68, the resulting radioconjugate enables PET visualisation of PSMA-expressing lesions.
Indications / reported uses
Used as the active ligand in gallium Ga-68 gozetotide (PSMA-11) injection for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated PSA.
The unlabelled ligand is not itself a radioactive imaging agent; diagnostic imaging requires the labelled gallium-68 product.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Gozetotide Environmental Risk Assessment (ERA) (the Gozetotide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.